Strategies for overcoming p-glycoprotein-mediated drug resistance in acute myeloblastic leukaemia

Leukemia

Volumn 18, Issue 12, 2004, Pages 1927-1930

  Pallis, M ^a   Russell, Nigel ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BIRICODAR; CASPASE 8; CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; CYCLOSPORIN; CYTARABINE; CYTOTOXIC AGENT; DAUNORUBICIN; ELACRIDAR; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDARUBICIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; QUININE; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL SURVIVAL; CELL VIABILITY; CLINICAL TRIAL; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; MOLECULAR MECHANICS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 11144337700     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403511     Document Type: Article

References (45)

1. Leith C. Multidrug resistance in leukemia. Curr Opin Hematol 1998; 5: 287-291.
2. Pallis M, Turzanski J, Higashi Y, Russell N. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype. Leuk Lymphoma 2002; 43: 1221-1228.
3. Del Poeta G, Venditti A, Stasi R, Aronica G, Cox MC, Buccisano F et al. P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. Leuk Res 1999; 23: 451-465.
4. Pallis M, Russell N. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000; 95: 2897-2904.
5. Johnstone RW, Ruefli AA, Tainton KM, Smyth MJ. A role for P-glycoprotein in regulating cell death. Leuk Lymphoma 2000; 38 1-11.
6. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997; 36: 11169-11178.
7. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 1998; 95: 7024-7029.
8. Johnstone R, Cretney E, Smyth M. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999; 93: 1075-1085.
9. Gollapudi S, Gupta S. Anti-P-glycoprotein antibody-induced apoptosis of activated peripheral blood lymphocytes: a possible role of P-glycoprotein in lymphocyte survival. J Clin Immunol 2001; 21 420-430.
10. Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J 2000; 17: 253-259.
11. Bezombes C, Maestre N, Laurent G, Levade T, Bettaieb A, Jaffrezou JP. Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the p-glycoprotein blocker PSC833. FASEB J 1998; 12: 101-109.
12. Lala P, Ito S, Lingwood CA. Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis. J Biol Chem 2000; 275: 6246-6251.
13. Veldman RJ, Klappe K, Hinrichs J, Hummel I, van der Schaaf G, Sietsma H et al. Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 2002; 16 1111-1113.
14. Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 2002; 99: 10347-10352.
15. Lavie Y, Cao H, Bursten SL, Giuliano AE, Cabot MC. Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 1996; 271: 19530-19536.
16. Itoh M, Kitano T, Watanabe M, Kondo T, Yabu T, Taguchi Y et al. Possible role of ceramide as an indicator of chemoresistance: decrease of ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukaemia. Clin Cancer Res 2003; 8: 415-423.
17. Shabbits JA, Mayer LD. P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 2002; 1: 205-213.
18. Turzanski J, Grundy M, Russell N, Pallis M. P-glycoprotein is implicated in the inhibition of ceramide induced apoptosis in acute myeloid leukaemia by more than one mechanism: evidence for the involvement of the glucosylceramide synthase pathway in TF1 but not in KG1a cells. Exp Hematol 2004, accepted for publication.
19. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-2307.
20. Wang CY, Mayo MW, Baldwin Jr AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996; 274: 784-787.
21. Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999; 19 5923-5929.
22. Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220-16225.
23. Mas VM, Hernandez H, Plo I, Bezombes C, Maestre N, Quillet-Mary A et al. Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin. Blood 2003; 101: 1543-1550.
24. Solary E, Witz B, Caillot D, Moreau P, Desablens B, Cahn JY et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996; 88: 1198-1205.
25. Wattel E, Solary E, Hecquet B, Caillot D, Ifrah N, Brion A et al. Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P glycoprotein: results of a randomized study. Br J Haematol 1998; 102: 1015-1024.
26. Solary E, Drenou B, Campos L, De Cremoux P, Mugneret F, Moreau P et al. Quinine as a multidrug resistance inhibitor: a phase III multicentric randomized study in adult de novo acute myelogenous leukemia. Blood 2003; 102: 1202-1210.
27. List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 2001; 98: 3212-3220.
28. Liu Yin JA, Wheatley K, Rees JK, Burnett AK. Comparison of 'sequential' vs 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 2001; 113: 713-726.
29. Baer MR, George SL, Dodge RK, O'Loughlin KL, Minderman H, Caligiuri MA et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100: 1224-1232.
30. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L et al. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol 2004; 22: 1078-1086.
31. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V et al. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 1997; 272: 1682-1687.
32. Goulding CW, Giuliano AE, Cabot MC. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett 2000; 149: 143-151.
33. Lin X, Sikkink RA, Rusnak F, Barber DL. Inhibition of calcineurin phosphatase activity by a calcineurin B homologous protein. J Biol Chem 1999; 274: 36125-36131.
34. Pallis M, Turzanski J, Harrison G, Wheatley K, Langabeer S, Burnett AK et al. Use of standardised flow cytometric determinants of multidrug resistance to analyse response to remission induction chemotherapy in patients with acute myeloblastic leukaemia. Br J Haematol 1999; 104: 307-312.
35. Pallis M, Turzanski J, Langabeer S, Russell N. Reproducible flow cytometric methodology for measuring multidrug resistance in leaukaemic blasts. In: Kaspers G, Pieters R, Veerman A (eds). Drug Resistance in leukaemia and Lymphoma III, Advances in Experimental Medicine and Biology, Vol 457. New York: Kluwer Academic, 1999. pp 77-88.
36. Pallis M, Das-Gupta E. The flow cytometric measurement of functional and phenotypic p-glycoprotein. In: Blumenthal DR (ed). Chemosensitivity: Methods and Protocols. Totowa, NJ: Humana Press, 2004.
37. Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D et al. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 1999; 13: 786-791.
38. Higashi Y, Turzanski J, Pallis M, Russell NH. Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. Br J Haematol 2000; 111: 565-569.
39. Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001; 98: 988-994.
40. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma 1997; 24: 533-537.
41. Newman A, Clutterbuck RD, Powles RL, Millar JL. Selective inhibition of primary acute myeloid leukaemia cell growth by lovastatin. Leukemia 1994; 8: 274-280.
42. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood 2003; 101: 3628-3634.
43. Maksumova L, Ohnishi K, Muratkhodjaev F, Zhang W, Pan L, Takeshita A et al. Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin. Leukemia 2000; 14: 1444-1450.
44. Lavie Y, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem 1998; 273: 32380-32383.
45. Hinrichs JW, Klappe K, Hummel I, Kok JW. ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells. J Biol Chem 2004; 279: 5734-5738.